Bio-Techne (TECH) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
23 Jan, 2026Mission and vision
Aims to improve quality of life by catalyzing advances in science and medicine.
Envisions unlocking the possibilities of science through collaboration.
Sustainability and governance
Achieved ISO 14001 certification at the largest manufacturing site and advanced energy, water, and waste management.
49% of global workforce and 47% of scientists are female; over 35% of U.S. workforce are minorities.
Board features diverse membership and is led by an independent chair.
Business overview and financials
FY2023 revenues exceeded $1.1B, with a market cap of ~$12B and 3,100 employees across 35 locations.
Consumables account for 81% of revenue, with instruments and services making up the remainder.
74% of revenue comes from Protein Sciences, 26% from Diagnostics & Genomics.
Major customer segments: pharma/biotech (50%), diagnostics (17%), academia (20%).
Latest events from Bio-Techne
- Growth led by pharma and China, with biotech and academic recovery fueling optimism.TECH
Leerink Global Healthcare Conference 202610 Mar 2026 - Strong growth in pharma, margin expansion, and M&A drive confidence for fiscal 2026.TECH
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Flat revenue, higher margins, and strong pharma/Asia growth offset mixed segment results.TECH
Q2 20264 Feb 2026 - Diagnostics & Genomics growth offset margin pressures, with recovery expected in FY25.TECH
Q4 20242 Feb 2026 - Growth in diagnostics and cell/gene therapy, resilient margins, and disciplined M&A drive outlook.TECH
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Growth verticals and innovation drive market outperformance and strong financial targets.TECH
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Growth verticals and innovation drive strong market outperformance and financial targets.TECH
The 44th Annual William Blair Growth Stock Conference31 Jan 2026 - Strong growth in proteomics and diagnostics drives expansion toward $2B revenue by FY26.TECH
Corporate presentation23 Jan 2026 - Innovative proteomics leader with strong growth, diverse portfolio, and sustainability focus.TECH
Corporate presentation23 Jan 2026